



For more information:
Marta Campos Martínez
mcampos@rovi.es
Tel: +34 91 244 44 22

Rovi reaches an agreement with Laboratoires Servier for the commercialisation of Thymanax® in Spain

Madrid – January 14, 2009 - Laboratorios Farmacéuticos Rovi (ROVI) and Les Laboratoires Servier (SERVIER), a French specialty pharmaceutical company, today announced that they have reached an agreement for SERVIER to appoint ROVI to sell and promote Thymanax® in Spain, in a co-marketing regime with Valdoxan®.

Thymanax®, whose active principle is agomelatine –an original molecule issued from the SERVIER Research–, is an innovative antidepressant which is indicated for adults with major depressive episodes. Thymanax® is the first melatonergic antidepressant with a totally innovative profile; it is an agonist at MT1 and MT2 melatonergic receptors and an antagonist at 5HT2C receptors. Unlike other pharmacological agents that have been used until now, the approach of this antidepressant is to restore the disturbed circadian rhythms of depressed patients, which present a crucial therapeutic target for those aiming to manage depression and to obtain better results in the treatment of depressive patients.

Depression is currently one of the main challenges of Spanish public health, and is the cause of significant suffering to an increasing number of patients and also to their families, with a major impact on their quality of life. In addition, depression is accompanied by high socio-economic costs, due to its consequences in the social and labour areas. The WHO (World Health Organisation) calculates that in 2020 major depression will be the second largest cause of disability, behind cardiovascular diseases.

According to data from IMS Health, the antidepressant market totalled 469 million euros in the twelve months to October 2009 (MAT October 2009), reflecting a unit growth of 3.3% in this period.

With Thymanax®, ROVI is increasing its product portfolio and is strengthening its commitment to the area of psychiatry, enabling it to offer mental health professionals a therapeutic alternative for the problems of depression, and hence contributing to improve the quality of life of patients suffering from this illness.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, said: “we are very excited by the potential of Thymanax®. Depressive episodes are increasingly frequent and are set to continue to increase exponentially in the coming years. This antidepressant provides depressed patients with an important new alternative in the treatment of depression, and it reflects the permanent goal of ROVI to satisfy the requirements of patients.”

About ROVI

ROVI is a fully integrated, profitable Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 23 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, bemiparin. ROVI’s research and development pipeline is focused primarily on addressing currently unmet medical needs by developing new LMWH-based products and expanding applications for its existing LMWH-based products. ROVI manufactures the active biological ingredient (bemiparin) for its principal proprietary product and product candidates and the injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. Additional information about ROVI is available on the company’s website: www.rovi.es

About SERVIER

SERVIER is the leading independent French pharmaceutical company. The group is established in 140 countries and 85% of SERVIER products are prescribed out of France. Sales turnover in 2008 rose to 3.7 billion euros. Almost 25% of SERVIER’s turnover is invested in Research and Development. Its principal therapeutic research orientations are cardiovascular diseases, diabetes, neuropsychiatric disorders, cancer, and osteoarticular diseases. More information is available at: www.servier.com.